评估循环microRNA谱在有症状患者中检测肺癌的应用
这项多中心队列研究纳入3102例有症状患者及对照,用机器学习分析血样microRNA谱,构建15-miRNA和14-miRNA特征区分肺癌与各类对照,验证集敏感性和特异性较高,提示miRNA特征或可作为微创肺癌检测的组成部分。
要点
- 15-miRNA特征区分肺癌与所有其他个体,验证集敏感性82.8%、特异性93.5%。
- 14-miRNA特征区分肺癌与非肿瘤性肺病,验证集敏感性96.4%、特异性88.6%。
- 14-miRNA特征区分早期肺癌与无肺癌个体,验证集敏感性76.3%、特异性97.5%。
核心结论
- 所识别的miRNA模式或可作为微创肺癌检测的组成部分,补充影像、痰细胞学和活检。
研究设计与样本
- 多中心队列研究,纳入TREND和COSYCONET研究中的3102例患者,2009年3月3日至2018年3月19日便利抽样入组。
- 3046例获得临床诊断,包括606例非小细胞和小细胞肺癌、593例非肿瘤性肺病、883例非肺部疾病、964例未受影响对照。
主要发现
- 15-miRNA特征区分肺癌与所有其他个体,验证集准确率91.4%(95% CI 91.0%-91.9%)、敏感性82.8%(81.5%-84.1%)、特异性93.5%(93.2%-93.8%)。
- 14-miRNA特征区分肺癌与非肿瘤性肺病,验证集准确率92.5%(92.1%-92.9%)、敏感性96.4%(95.9%-96.9%)、特异性88.6%(88.1%-89.2%)。
- 14-miRNA特征区分早期肺癌与所有无肺癌个体,验证集准确率95.9%(95.7%-96.2%)、敏感性76.3%(74.5%-78.0%)、特异性97.5%(97.2%-97.7%)。
关键数值与推荐
- 采用机器学习方法评估全基因组miRNA谱,样本等分为训练集和验证集。
- 15-miRNA特征用于肺癌与所有其他个体的鉴别。
- 14-miRNA特征用于肺癌与非肿瘤性肺病的鉴别。
- 14-miRNA特征用于早期肺癌与所有无肺癌个体的鉴别。
临床怎么用
- 对于有症状患者,血源性miRNA特征或可作为微创检测工具,辅助影像、痰细胞学和活检进行肺癌检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The overall low survival rate of patients with lung cancer calls for improved detection tools to enable better treatment options and improved patient outcomes. Multivariable molecular signatures, such as blood-borne microRNA (miRNA) signatures, may have high rates of sensitivity and specificity but require additional studies with large cohorts and standardized measurements to confirm the generalizability of miRNA signatures. OBJECTIVE: To investigate the use of blood-borne miRNAs as potential circulating markers for detecting lung cancer in an extended cohort of symptomatic patients and control participants. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, cohort study included patients from case-control and cohort studies (TREND and COSYCONET) with 3102 patients being enrolled by convenience sampling between March 3, 2009, and March 19, 2018. For the cohort study TREND, population sampling was performed. Clinical diagnoses were obtained for 3046 patients (606 patients with non-small cell and small cell lung cancer, 593 patients with nontumor lung diseases, 883 patients with diseases not affecting the lung, and 964 unaffected control participants). No samples were removed because of experimental issues. The collected data were analyzed between April 2018 and November 2019. MAIN OUTCOMES AND MEASURES: Sensitivity and specificity of liquid biopsy using miRNA signatures for detection of lung cancer. RESULTS: A total of 3102 patients with a mean (SD) age of 61.1 (16.2) years were enrolled. Data on the sex of the participants were available for 2856 participants; 1727 (60.5%) were men. Genome-wide miRNA profiles of blood samples from 3046 individuals were evaluated by machine-learning methods. Three classification scenarios were investigated by splitting the samples equally into training and validation sets. First, a 15-miRNA signature from the training set was used to distinguish patients diagnosed with lung cancer from all other individuals in the validation set with an accuracy of 91.4% (95% CI, 91.0%-91.9%), a sensitivity of 82.8% (95% CI, 81.5%-84.1%), and a specificity of 93.5% (95% CI, 93.2%-93.8%). Second, a 14-miRNA signature from the training set was used to distinguish patients with lung cancer from patients with nontumor lung diseases in the validation set with an accuracy of 92.5% (95% CI, 92.1%-92.9%), sensitivity of 96.4% (95% CI, 95.9%-96.9%), and specificity of 88.6% (95% CI, 88.1%-89.2%). Third, a 14-miRNA signature from the training set was used to distinguish patients with early-stage lung cancer from all individuals without lung cancer in the validation set with an accuracy of 95.9% (95% CI, 95.7%-96.2%), sensitivity of 76.3% (95% CI, 74.5%-78.0%), and specificity of 97.5% (95% CI, 97.2%-97.7%). CONCLUSIONS AND RELEVANCE: The findings of the study suggest that the identified patterns of miRNAs may be used as a component of a minimally invasive lung cancer test, complementing imaging, sputum cytology, and biopsy tests.
引用
- Fehlmann T, Kahraman M, Ludwig N, et al. Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients. JAMA Oncol. 2020. PMID: 32134442. doi:10.1001/jamaoncol.2020.0001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。